RA(Regulatory Affairs) ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ - ¼ºñ½ºº°, Ä«Å×°í¸®º°, Á¦Ç° À¯Çüº°, ±â¾÷ ±Ô¸ðº°, Á¦Ç° ½ºÅ×ÀÌÁöº°, ÀûÀÀÁõº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® µ¿Çâ(2025-2030³â)
Regulatory Affairs Market Size, Share & Trends Analysis Report By Services (Regulatory Consulting, Legal Representation), By Categories, By Type, By Company Size, By Product Stage, By Indication, By End Use, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå
:
1726250
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2025³â 04¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 200 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
RA(Regulatory Affairs) ½ÃÀåÀÇ ¼ºÀå ¹× µ¿Çâ
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é ¼¼°èÀÇ RA(Regulatory Affairs) ½ÃÀå ±Ô¸ð´Â 2025-2030³â CAGR 8.80%·Î È®´ëµÉ Àü¸ÁÀ̸ç, 2030³â¿¡´Â 271¾ï 8,000¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀÔ´Ï´Ù.
ÀÌ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ¿äÀÎÀ¸·Î´Â »ç¾÷ Ȱµ¿À̳ª Áö¿ª¿¡ µû¶ó º¯ÈÇÏ´Â ±ÔÁ¦ ¿ä°Ç, ±ÔÁ¦ ´ç±¹¿¡ ÀÇÇÑ ½ÂÀÎÀÇ ½Å¼ÓÈ¿¡ ¼ö¹ÝÇÏ´Â ÀÓ»ó °Ë»ç³ª ÀǾàǰ ½ÂÀÎ Áõ°¡, ±ÔÁ¦ ´ç±¹¿ë ¼ÒÇÁÆ®¿þ¾îÀÇ ±â¼ú Áøº¸ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °³º°È ÀǾàǰÀÇ ÁøÈ, ±â¾÷ÀÌ ÇÙ½ÉÀûÀÎ »ç¾÷ Ȱµ¿¿¡ ÁýÁßÇÒ Çʿ伺ÀÇ Áõ´ë, °æÁ¦Àû ¹× ½ÃÀå °æÀïÀû ¾Ð·Â µîµµ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ´Â ¿äÀÎÀÔ´Ï´Ù.
COVID-19 °¨¿°°ú ½Î¿ì´Â µ¥ ÇÊ¿äÇÑ ¹é½Å°ú ÀÇ·á Á¦Ç°À» ½Å¼ÓÇÏ°Ô °³¹ßÇϱâ À§ÇØ Á¦¾à ȸ»ç¿Í ±ÔÁ¦ ´ç±¹ÀÌ ¼ÕÀ» Àâ¾Ò½À´Ï´Ù. ±ÔÁ¦´ç±¹Àº ÀÓ»ó°Ë»ç ÁßÀΠȯÀÚ¿Í ÀηÂÀÇ ¾ÈÀüÀ» È®º¸ÇÏ°í µ¥ÀÌÅÍ ¹«°á¼º°ú ÀûÁ¤ÇÑ ½ÇÇè½Ç ¾÷¹«°¡ À¯ÁöµÉ ¼ö ÀÖµµ·Ï ¼ö¸¹Àº ¿¹¹æ Á¶Ä¡¸¦ °±¸Çϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯, Èñ±Íº´¿ëÀǾàǰ, °³º°ÈÀǾàǰ, µ¿¹ÝÁø´Ü¾à, ÀûÀÀ°Ë»ç µðÀÚÀÎ µîÀÇ ½ÃÀå ¼ºÀåÀº ÀÌ·¯ÇÑ ºÎ¹®¿¡¼ ±ÔÁ¦´ç±¹ÀÇ Àü¹®¼º¿¡ ´ëÇÑ ¼ö¿ä¸¦ ²ø¾î¿Ã¸± °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±â¾÷ÀÌ »õ·Î¿î ºÎ¹®¿¡ ÁøÃâÇÔ¿¡ µû¶ó ±ÔÁ¦¸¦ ÁؼöÇÒ Çʿ伺ÀÌ ³ô¾ÆÁö°í, ¾à»ç ¾÷¹«ÀÇ Àü¹® Áö½ÄÀ» °¡Áø Àü¹® ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ½É·ºÆ®, º¤Æ¼ºò½º, ¹Ð¼¼¶ó, Ű³×·¹Æ® µî »ý¹°Á¦Á¦ÀÇ Æ¯Çã°¡ ¸¸·áµÇ¸é¼ ¹ÙÀÌ¿À½Ã¹Ð·¯ ¼ö¿ä¿Í °³¹ßÀÌ Áõ°¡Çϰí ÀÖ¾î ¾à»ç¼ºñ½º ¼ö¿ä¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
¸ÂÃãÇü ÀÇ·á ½ÃÀå¿¡¼ ÁÖµµ±ÇÀ» Àâ±â À§ÇØ ¿©·¯ ±â¾÷ÀÌ Á¦ÈÞ ¹× ½ÅÁ¦Ç° °³Ã´¿¡ Àû±ØÀûÀ¸·Î ³ë·ÂÇϰí ÀÖÀ¸¸ç, ¾à»ç ¾÷¹« Áö¿øÀÌ ÇÊ¿äÇÏ´Ù´Â °ÍÀ» º¸¿©ÁÝ´Ï´Ù. ¿¹¸¦ µé¾î 2020³â 5¿ù Regeneron Pharmaceuticals, Inc.´Â ¸ÂÃãÇü ÀÇ·á ¹× Àΰ£ À¯ÀüÇÐÀÇ Áøº¸¸¦ ¼³°èÇϱâ À§ÇØ Colorado Center for Personalized Medicine°ú Á¦ÈÞÇß½À´Ï´Ù.
RA(Regulatory Affairs) ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
2024³â¿¡´Â ¾Æ¿ô¼Ò½Ì ºÎ¹®ÀÌ 59.05%ÀÇ Á¡À¯À²À» Â÷ÁöÇØ ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀº ÁÖ·Î Á¦¾à±â¾÷À̳ª ÀÇ·á±â±â ±â¾÷ÀÌ »ç³»¿¡ ¾ø´Â Àü¹®ÀûÀÎ Àü¹®Áö½ÄÀ̳ª ¸®¼Ò½º¸¦ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¾Æ¿ô¼Ò½Ì¿¡ ÁÖ·ÂÇÏ°Ô µÇ¾ú±â ¶§¹®ÀÔ´Ï´Ù.
·¹±Ö·¯ Æ®¸® ¶óÀÌÆÃ ¹× ÆÛºí¸®½Ì ºÎ¹®Àº 2024³â ½ÃÀå¿¡¼ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀº ¿©·¯ Á¦¾à ¹× ¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷ÀÌ ºñ¿ëÀ» Àý°¨Çϰí Àü·«Àû ÇÁ·ÎÁ§Æ®¸¦ ¿ì¼±½ÃÇϸç, Á÷¿ø ±³À° ½Ã°£À» ´ÜÃàÇϰí, ÀüüÀûÀÎ È¿À²¼ºÀ» Çâ»ó½Ã۸ç, ´õ ³ôÀº À¯¿¬¼ºÀ» Á¦°øÇÏ´Â µ¥ ±âÀÎÇÕ´Ï´Ù.
2024³â RA(Regulatory Affairs) ½ÃÀåÀº ÀǾàǰ ºÎ¹®ÀÌ Áö¹èÀûÀ̾ú½À´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀº ´Ù¾çÇÑ ±ÔÁ¦¿Í ÇÁ·Î¼¼½º¿¡ °ü·ÃµÈ °¢ ´Ü°è¿¡¼ÀÇ °ü·Ã ±ÔÁ¦´ç±¹¿¡ ´ëÇÑ ½Åû ¹× ¹®¼ÀÛ¼º¿¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù.
2024³â¿¡´Â ¾Ï ¿µ¿ªÀÌ ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀº È¿°úÀûÀÌ°í ¾ÈÀüÇÑ Ä¡·á ¿É¼ÇÀ» ÇÊ¿ä·Î ÇÏ´Â ¾Ï À¯º´·üÀÇ Áõ°¡¿¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù.
ÀÓ»ó ¿¬±¸°¡ 2024³â ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù. ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í »õ·Î¿î ÁúȯÀÇ ÃâÇöÀÌ ´õÇØÁ®, º¸´Ù ÁÁÀº Ä¡·á ¿É¼Ç¿¡ ¼ö¿ä°¡ ³ô¾ÆÁö°í, ȯÀÚÀÇ Áõ´ëÇÏ´Â ¿ä±¸¿¡ ´ëÀÀÇϱâ À§Çؼ ¼¼°èÀûÀ¸·Î ½Ç½ÃµÇ´Â ÀÓ»ó °Ë»çÀÇ ¼ö°¡ ÇÑÃþ ´õ Áõ°¡ÇÕ´Ï´Ù.
2024³â ½ÃÀå ±Ô¸ð´Â Áß°ß ±â¾÷ ±Ô¸ð ºÎ¹®ÀÌ Áö¹èÀûÀ̾ú½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î ºñ»óÀå ±â¾÷À» Áß½ÉÀ¸·Î ÇÏ´Â Áß°ß±â¾÷ÀÇ À§»óÀÌ Å©±â ¶§¹®ÀÔ´Ï´Ù.
2024³â ½ÃÀå ±Ô¸ð´Â Á¦¾à±â¾÷ÀÌ ¾ÐµµÀûÀ̾ú½À´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀº ½ÂÀÎ ÀǾàǰ ¼öÀÇ Áõ°¡¿Í ¸Â¹°·Á ¿¬±¸°³¹ß Ȱµ¿ÀÌ È°¹ßÇØÁö°í ÀÖ´Â °Í¿¡ ±âÀÎÇÑ´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ RA(Regulatory Affairs) ½ÃÀåÀº ¼¼°è ½ÃÀåÀ» ¼®±ÇÇØ 2024³â¿¡´Â 38.03%ÀÇ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý ¹× ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå RA(Regulatory Affairs) ½ÃÀåÀÇ º¯¼ö, µ¿Çâ ¹× ¹üÀ§
½ÃÀå °èÅëÀÇ Àü¸Á
¸ð ½ÃÀå Àü¸Á
°ü·Ã ¹× º¸Á¶ÀûÀÎ ½ÃÀå Àü¸Á
½ÃÀå ¿ªÇÐ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
»ê¾÷ ½ÃÀå ºÐ¼® µµ±¸
»ê¾÷ ºÐ¼®-Porter's Five Forces ºÐ¼®
PESTEL ºÐ¼®
COVID-19ÀÇ ¿µÇ⠺м®
Á¦4Àå RA(Regulatory Affairs) ½ÃÀå : ¼ºñ½ºº° ÃßÁ¤ ¹× µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ RA(Regulatory Affairs) ½ÃÀå : ¼ºñ½ºº° º¯µ¿ ºÐ¼®
¼¼°èÀÇ RA(Regulatory Affairs) ½ÃÀå : ¼ºñ½ºº° ±Ô¸ð ¹× µ¿Ç⠺м®(2018-2030³â)
±ÔÁ¦ ÄÁ¼³ÆÃ
¹ýÀû ´ë¸®
±ÔÁ¦ ¹®¼ÀÇ ÁýÇÊ ¹× ÃâÆÇ
Á¦Ç° µî·Ï ¹× ÀÓ»ó °Ë»ç ½Åû
±âŸ
Á¦5Àå RA(Regulatory Affairs) ½ÃÀå : Ä«Å×°í¸®º° ÃßÁ¤ ¹× µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ RA(Regulatory Affairs) ½ÃÀå : Ä«Å×°í¸®º° º¯µ¿ ºÐ¼®
¼¼°èÀÇ RA(Regulatory Affairs) ½ÃÀå : Ä«Å×°í¸®º° ±Ô¸ð ¹× µ¿Ç⠺м®(2018-2030³â)
¾à
»ý¹°Á¦Á¦
¹ÙÀÌ¿À½Ã¹Ð·¯
ÀÇ·á±â±â
Á¦6Àå RA(Regulatory Affairs) ½ÃÀå : ÀûÀÀÁõº° ÃßÁ¤ ¹× µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ RA(Regulatory Affairs) ½ÃÀå : ÀûÀÀÁõº° º¯µ¿ ºÐ¼®
¼¼°èÀÇ RA(Regulatory Affairs) ½ÃÀå : ÀûÀÀÁõº° ±Ô¸ð ¹× µ¿Ç⠺м®(2018-2030³â)
Á¾¾çÇÐ
½Å°æÇÐ
½ÉÀ庴ÇÐ
¸é¿ªÇÐ
±âŸ
Á¦7Àå RA(Regulatory Affairs) ½ÃÀå : Á¦Ç° ½ºÅ×ÀÌÁöº° ÃßÁ¤ ¹× µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ RA(Regulatory Affairs) ½ÃÀå : Á¦Ç° ½ºÅ×ÀÌÁöº° º¯µ¿ ºÐ¼®
¼¼°èÀÇ RA(Regulatory Affairs) ½ÃÀå : Á¦Ç° ½ºÅ×ÀÌÁöº° ±Ô¸ð ¹× µ¿Ç⠺м®(2018-2030³â)
ÀüÀÓ»ó
ÀÓ»ó ¿¬±¸
½ÃÆÇÀü ½ÂÀÎ(PMA)
Á¦8Àå RA(Regulatory Affairs) ½ÃÀå : À¯Çüº° ÃßÁ¤ ¹× µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ RA(Regulatory Affairs) ½ÃÀå : À¯Çüº° º¯µ¿ ºÐ¼®
¼¼°èÀÇ RA(Regulatory Affairs) ½ÃÀå : À¯Çüº° ±Ô¸ð ¹× µ¿Ç⠺м®(2018-2030³â)
»ç³»
¾Æ¿ô¼Ò½Ì
Á¦9Àå RA(Regulatory Affairs) ½ÃÀå : ±â¾÷ ±Ô¸ðº° ÃßÁ¤ ¹× µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ RA(Regulatory Affairs) ½ÃÀå : ±â¾÷ ±Ô¸ðº° º¯µ¿ ºÐ¼®
¼¼°èÀÇ RA(Regulatory Affairs) ½ÃÀå : ±â¾÷ ±Ô¸ðº° ±Ô¸ð ¹× µ¿Ç⠺м®(2018-2030³â)
¼Ò
Áß
´ë
Á¦10Àå RA(Regulatory Affairs) ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤ ¹× µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ RA(Regulatory Affairs) ½ÃÀå : ÃÖÁ¾ ¿ëµµº° º¯µ¿ ºÐ¼®
¼¼°èÀÇ RA(Regulatory Affairs) ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ±Ô¸ð ¹× µ¿Ç⠺м®(2018-2030³â)
ÀÇ·á±â±â ±â¾÷
Á¦¾àȸ»ç
¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
Á¦11Àå RA(Regulatory Affairs) ½ÃÀå : Áö¿ªº° ÃßÁ¤ ¹× µ¿Ç⠺м®
Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â, 2030³â)
Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
ºÏ¹Ì
À¯·´
¿µ±¹
µ¶ÀÏ
ÇÁ¶û½º
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
µ§¸¶Å©
³ë¸£¿þÀÌ
³×´ú¶õµå
½ºÀ§½º
½º¿þµ§
¾Æ½Ã¾ÆÅÂÆò¾ç
ÀϺ»
Áß±¹
Àεµ
È£ÁÖ
Çѱ¹
ű¹
Àεµ³×½Ã¾Æ
¸»·¹À̽þÆ
½Ì°¡Æ÷¸£
´ë¸¸
¶óƾ¾Æ¸Þ¸®Ä«
ºê¶óÁú
¾Æ¸£ÇîÆ¼³ª
ÄÝ·Òºñ¾Æ
Ä¥·¹
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
³²¾ÆÇÁ¸®Ä«
»ç¿ìµð¾Æ¶óºñ¾Æ
¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
ÀÌÁýÆ®
À̽º¶ó¿¤
Äí¿þÀÌÆ®
Á¦12Àå °æÀï ±¸µµ
°æÀïÀÇ ºÐ·ù
±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ¹× Æò°¡ ºÐ¼®(2024³â)
±â¾÷ ÇÁ·ÎÆÄÀÏ
Accell Clinical Research, LLC
Genpact
Criterium, Inc.
ICON plc
iuvo BioScience, LLC.
WuXi AppTec
Medpace
Charles River Laboratories
Laboratory Corporation of America Holdings
Parexel International(MA) Corporation
Freyr
PHARMALEX GMBH
SSI Strategy LLC
Pharmexon
Qvigilance
BlueReg
Cambridge Regulatory Services
VCLS
AJY
¿µ¹® ¸ñÂ÷
Regulatory Affairs Market Growth & Trends:
The global regulatory affairs market size is expected to reach USD 27.18 billion by 2030, expanding at a CAGR of 8.80% from 2025 to 2030, according to a new report by Grand View Research, Inc. The factors expected to contribute to the growth of this market include changing regulatory requirements based on business activities and geographies, an increase in clinical trials & drug approvals along with accelerated regulatory approval, and technological advancement in regulatory software. Also, the evolution of personalized medicines, the increasing need for companies to focus on core business activities, and economic and competitive pressures are other factors that are contributing to the growth of the market.
The pharmaceutical and regulatory agencies joined forces to rapidly develop vaccines and medical products required to fight against the COVID-19 infection. The regulatory authorities take numerous precautions to ensure patient and personnel safety during a clinical trial, as well as data integrity and good laboratory practices are maintained. Growth in markets for biosimilars, orphan drugs, personalized medicines, companion diagnostics, and adaptive trial designs is projected to boost the demand for regulatory specialization in these areas. As companies venture into newer fields, the growing need to comply with regulations is boosting the demand for specialized service providers with expertise in regulatory affairs. Patent expiration of biologics, such as Simulect, Vectibix, Mircera, and Kineret, is increasing the demand and development of biosimilars, thereby contributing to the demand for regulatory services.
Several companies are actively involved in collaborations and new product development to gain leadership in the personalized medicine market, indicating a need for supportive regulatory affairs. For instance, in May 2020, Regeneron Pharmaceuticals, Inc. collaborated with Colorado Center for Personalized Medicine to design advancements in personalized medicine and human genetics.
Regulatory Affairs Market Report Highlights:
The outsourcing segment dominated the market with a share of 59.05% in 2024. The growth of the segment is mainly due to the growing focus of the pharmaceutical and medical device companies to outsource their activities as it allows access to specialized expertise and resources that they may not have in-house.
The regulatory writing & publishing segment held a significant share of the market in 2024. The growth of the segment is attributed to several pharmaceutical or biopharmaceutical companies reducing costs, prioritizing strategic projects, reducing staff training time, and improving overall efficiency, as well as providing greater flexibility.
The drugs segment dominated the regulatory affairs market in 2024. The growth of the segment can be attributed to various regulations and related regulatory submissions/documentation at each of the steps involved in the process.
The oncology segment dominated the market in 2024. The growth of the segment is due to the increasing prevalence of cancer, which requires effective and safe treatment options.
Clinical studies dominated the market in 2024. The increasing prevalence of chronic diseases coupled with the emergence of new diseases will increase the demand for better treatment options, further growing the number of clinical trials conducted globally to meet the growing needs of the patients.
The medium company size segment dominated the market in 2024. The growth of the market is mainly due to the strong presence of several mid-sized established firms, mainly which are privately held.
The pharmaceutical companies segment dominated the market in 2024. The growth of the segment is due to growing research and development activities coupled with an increase in the number of approved pharmaceutical products.
The regulatory affairs market in Asia Pacific dominated the global industry and accounted for a 38.03% share in 2024.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Regional Scope
1.1.2. Estimates and Forecast Timeline
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Purchased Database
1.3.3. GVR's Internal Database
1.3.4. Secondary Sources
1.3.5. Primary Research
1.4. Information or Data Analysis
1.4.1. Information Analysis
1.4.2. Market Formulation & Data Visualization
1.4.3. Data Validation & Publishing
1.5. Model Details
1.5.1. Commodity Flow Analysis (Model 1)
1.5.2. Top Down Market Estimation (Model 2)
1.5.3. Value-Chain-Based Sizing & Forecasting (Model 3)
1.5.4. Multivariate Analysis (Model 4)
1.6. List of Secondary Sources
1.7. List of Abbreviations
1.8. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. Regulatory Affairs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Changing regulatory landscape
3.2.1.2. Entry of companies into the global market
3.2.1.3. Life science companies focusing on their core competencies
3.2.1.4. Economic and competitive pressures
3.2.1.5. Demand for the faster approval process for breakthrough drugs and devices
3.2.1.6. Growth in emerging areas such as personalized medicine, biosimilars, and orphan drugs
3.2.2. Market Restraint Analysis
3.2.2.1. Risk Associated with Data Security
3.2.2.2. Monitoring Issues and Lack of Standardization
3.3. Industry Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Regulatory Affairs Market: Services Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Regulatory Affairs Market Services Movement Analysis
4.3. Global Regulatory Affairs Market Size & Trend Analysis, by Services, 2018 to 2030 (USD Million)
4.4. Regulatory Consulting
4.4.1. Regulatory consulting market estimates and forecasts, 2018 - 2030 (USD Million)
4.5. Legal Representation
4.5.1. Legal representation market estimates and forecasts, 2018 - 2030 (USD Million)
4.6. Regulatory Writing & Publishing
4.6.1. Regulatory writing & publishing market estimates and forecasts, 2018 - 2030 (USD Million)
4.6.1.1. Writing
4.6.1.1.1. Writing market estimates and forecasts, 2018 - 2030 (USD Million)
4.6.1.2. Publishing
4.6.1.2.1. Publishing market estimates and forecasts, 2018 - 2030 (USD Million)
4.7. Product Registration & Clinical Trial Applications
4.7.1. Product registration & clinical trial applications market estimates and forecasts, 2018 - 2030 (USD Million)
4.8. Other Services
4.8.1. Other services market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 5. Regulatory Affairs Market: Category Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Regulatory Affairs Market Category Movement Analysis
5.3. Global Regulatory Affairs Market Size & Trend Analysis, by Category, 2018 to 2030 (USD Million)
5.4. Drugs
5.4.1. Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
5.4.2. Innovator
5.4.2.1. Innovator market estimates and forecasts, 2018 - 2030 (USD Million)
5.4.2.2. Preclinical
5.4.2.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
5.4.2.3. Clinical
5.4.2.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
5.4.2.4. Pre-Market Approval (PMA)
5.4.2.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
5.4.3. Generics
5.4.3.1. Generics market estimates and forecasts, 2018 - 2030 (USD Million)
5.4.3.2. Preclinical
5.4.3.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
5.4.3.3. Clinical
5.4.3.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
5.4.3.4. Pre-Market Approval (PMA)
5.4.3.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
5.5. Biologics
5.5.1. Biologics market estimates and forecasts, 2018 - 2030 (USD Million)
5.5.2. Biotech
5.5.2.1. Biotech market estimates and forecasts, 2018 - 2030 (USD Million)
5.5.2.2. Preclinical
5.5.2.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
5.5.2.3. Clinical
5.5.2.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
5.5.2.4. Pre-Market Approval (PMA)
5.5.2.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
5.5.3. ATMP
5.5.3.1. ATMP market estimates and forecasts, 2018 - 2030 (USD Million)
5.5.3.2. Preclinical
5.5.3.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
5.5.3.3. Clinical
5.5.3.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
5.5.3.4. Pre-Market Approval (PMA)
5.5.3.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
5.6. Biosimilars
5.6.1. Biosimilars market estimates and forecasts, 2018 - 2030 (USD Million)
5.6.1.1. Preclinical
5.6.1.1.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
5.6.1.2. Clinical
5.6.1.2.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
5.6.1.3. Pre-Market Approval (PMA)
5.6.1.3.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
5.7. Medical Devices
5.7.1. Medical devices market estimates and forecasts, 2018 - 2030 (USD Million)
5.7.2. Diagnostics
5.7.2.1. Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
5.7.2.2. Preclinical
5.7.2.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
5.7.2.3. Clinical
5.7.2.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
5.7.2.4. Pre-Market Approval (PMA)
5.7.2.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
5.7.3. Therapeutics
5.7.3.1. Therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
5.7.3.2. Preclinical
5.7.3.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
5.7.3.3. Clinical
5.7.3.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
5.7.3.4. Pre-Market Approval (PMA)
5.7.3.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 6. Regulatory Affairs Market: Indication Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Regulatory Affairs Market Indication Movement Analysis
6.3. Global Regulatory Affairs Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
6.4. Oncology
6.4.1. Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
6.5. Neurology
6.5.1. Neurology market estimates and forecasts, 2018 - 2030 (USD Million)
6.6. Cardiology
6.6.1. Cardiology market estimates and forecasts, 2018 - 2030 (USD Million)
6.7. Immunology
6.7.1. Immunology market estimates and forecasts, 2018 - 2030 (USD Million)
6.8. Others
6.8.1.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 7. Regulatory Affairs Market: Product Stage Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Global Regulatory Affairs Market Product Stage Movement Analysis
7.3. Global Regulatory Affairs Market Size & Trend Analysis, by Product Stage, 2018 to 2030 (USD Million)
7.4. Preclinical
7.4.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
7.5. Clinical studies
7.5.1. Clinical studies market estimates and forecasts, 2018 - 2030 (USD Million)
7.6. Pre-Market Approval (PMA)
7.6.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 8. Regulatory Affairs Market: Type Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Global Regulatory Affairs Market Type Movement Analysis
8.3. Global Regulatory Affairs Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
8.4. In-house
8.4.1. In-house market estimates and forecasts, 2018 - 2030 (USD Million)
8.5. Outsourced
8.5.1. Outsourced market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 9. Regulatory Affairs Market: Company Size Estimates & Trend Analysis
9.1. Segment Dashboard
9.2. Global Regulatory Affairs Market Company Size Movement Analysis
9.3. Global Regulatory Affairs Market Size & Trend Analysis, by Company Size, 2018 to 2030 (USD Million)
9.4. Small
9.4.1. Small market estimates and forecasts, 2018 - 2030 (USD Million)
9.5. Medium
9.5.1. Medium market estimates and forecasts, 2018 - 2030 (USD Million)
9.6. Large
9.6.1. Large market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 10. Regulatory Affairs Market: End-use Estimates & Trend Analysis
10.1. Segment Dashboard
10.2. Global Regulatory Affairs Market End-use Movement Analysis
10.3. Global Regulatory Affairs Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
10.4. Medical Device Companies
10.4.1. Medical device companies market estimates and forecasts, 2018 - 2030 (USD Million)
10.5. Pharmaceutical Companies
10.5.1. Pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
10.6. Biotechnology Companies
10.6.1. Biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 11. Regulatory Affairs Market: Regional Estimates & Trend Analysis
11.1. Regional Market Share Analysis, 2024 & 2030
11.2. Regional Market Dashboard
11.3. Market Size & Forecasts Trend Analysis, 2018 to 2030 (USD Million)
11.4. North America
11.4.1. North America Market Estimates and Forecasts 2018 to 2030, (USD Million)
11.4.2. U.S.
11.4.2.1. Key country dynamics
11.4.2.2. Competitive scenario
11.4.2.3. Regulatory scenario
11.4.2.4. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
11.4.3. Canada
11.4.3.1. Key country dynamics
11.4.3.2. Competitive scenario
11.4.3.3. Regulatory scenario
11.4.3.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
11.4.4. Mexico
11.4.4.1. Key country dynamics
11.4.4.2. Competitive scenario
11.4.4.3. Regulatory scenario
11.4.4.4. Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
11.5. Europe
11.5.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
11.5.2. UK
11.5.2.1. Key country dynamics
11.5.2.2. Competitive scenario
11.5.2.3. Regulatory scenario
11.5.2.4. UK market estimates and forecasts, 2018 - 2030 (USD Million)
11.5.3. Germany
11.5.3.1. Key country dynamics
11.5.3.2. Competitive scenario
11.5.3.3. Regulatory scenario
11.5.3.4. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
11.5.4. France
11.5.4.1. Key country dynamics
11.5.4.2. Competitive scenario
11.5.4.3. Regulatory scenario
11.5.4.4. France market estimates and forecasts, 2018 - 2030 (USD Million)
11.5.5. Italy
11.5.5.1. Key country dynamics
11.5.5.2. Competitive scenario
11.5.5.3. Regulatory scenario
11.5.5.4. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
11.5.6. Spain
11.5.6.1. Key country dynamics
11.5.6.2. Competitive scenario
11.5.6.3. Regulatory scenario
11.5.6.4. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
11.5.7. Denmark
11.5.7.1. Key country dynamics
11.5.7.2. Competitive scenario
11.5.7.3. Regulatory scenario
11.5.7.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
11.5.8. Norway
11.5.8.1. Key country dynamics
11.5.8.2. Competitive scenario
11.5.8.3. Regulatory scenario
11.5.8.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
11.5.9. Netherlands
11.5.9.1. Key country dynamics
11.5.9.2. Competitive scenario
11.5.9.3. Regulatory scenario
11.5.9.4. Netherlands market estimates and forecasts, 2018 - 2030 (USD Million)
11.5.10. Switzerland
11.5.10.1. Key country dynamics
11.5.10.2. Competitive scenario
11.5.10.3. Regulatory scenario
11.5.10.4. Switzerland market estimates and forecasts, 2018 - 2030 (USD Million)
11.5.11. Sweden
11.5.11.1. Key country dynamics
11.5.11.2. Competitive scenario
11.5.11.3. Regulatory scenario
11.5.11.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
11.6. Asia Pacific
11.6.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
11.6.2. Japan
11.6.2.1. Key country dynamics
11.6.2.2. Competitive scenario
11.6.2.3. Regulatory scenario
11.6.2.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
11.6.3. China
11.6.3.1. Key country dynamics
11.6.3.2. Competitive scenario
11.6.3.3. Regulatory scenario
11.6.3.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
11.6.4. India
11.6.4.1. Key country dynamics
11.6.4.2. Competitive scenario
11.6.4.3. Regulatory scenario
11.6.4.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
11.6.5. Australia
11.6.5.1. Key country dynamics
11.6.5.2. Competitive scenario
11.6.5.3. Regulatory scenario
11.6.5.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
11.6.6. South Korea
11.6.6.1. Key country dynamics
11.6.6.2. Competitive scenario
11.6.6.3. Regulatory scenario
11.6.6.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
11.6.7. Thailand
11.6.7.1. Key country dynamics
11.6.7.2. Competitive scenario
11.6.7.3. Regulatory scenario
11.6.7.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
11.6.8. Indonesia
11.6.8.1. Key country dynamics
11.6.8.2. Competitive scenario
11.6.8.3. Regulatory scenario
11.6.8.4. Indonesia market estimates and forecasts, 2018 - 2030 (USD Million)
11.6.9. Malaysia
11.6.9.1. Key country dynamics
11.6.9.2. Competitive scenario
11.6.9.3. Regulatory scenario
11.6.9.4. Malaysia market estimates and forecasts, 2018 - 2030 (USD Million)
11.6.10. Singapore
11.6.10.1. Key country dynamics
11.6.10.2. Competitive scenario
11.6.10.3. Regulatory scenario
11.6.10.4. Singapore market estimates and forecasts, 2018 - 2030 (USD Million)
11.6.11. Taiwan
11.6.11.1. Key country dynamics
11.6.11.2. Competitive scenario
11.6.11.3. Regulatory scenario
11.6.11.4. Taiwan market estimates and forecasts, 2018 - 2030 (USD Million)
11.7. Latin America
11.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
11.7.2. Brazil
11.7.2.1. Key country dynamics
11.7.2.2. Competitive scenario
11.7.2.3. Regulatory scenario
11.7.2.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
11.7.3. Argentina
11.7.3.1. Key country dynamics
11.7.3.2. Competitive scenario
11.7.3.3. Regulatory scenario
11.7.3.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
11.7.4. Colombia
11.7.4.1. Key country dynamics
11.7.4.2. Competitive scenario
11.7.4.3. Regulatory scenario
11.7.4.4. Colombia market estimates and forecasts, 2018 - 2030 (USD Million)
11.7.5. Chile
11.7.5.1. Key country dynamics
11.7.5.2. Competitive scenario
11.7.5.3. Regulatory scenario
11.7.5.4. Chile market estimates and forecasts, 2018 - 2030 (USD Million)
11.8. MEA
11.8.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
11.8.2. South Africa
11.8.2.1. Key country dynamics
11.8.2.2. Competitive scenario
11.8.2.3. Regulatory scenario
11.8.2.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
11.8.3. Saudi Arabia
11.8.3.1. Key country dynamics
11.8.3.2. Competitive scenario
11.8.3.3. Regulatory scenario
11.8.3.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
11.8.4. UAE
11.8.4.1. Key country dynamics
11.8.4.2. Competitive scenario
11.8.4.3. Regulatory scenario
11.8.4.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
11.8.5. Egypt
11.8.5.1. Key country dynamics
11.8.5.2. Competitive scenario
11.8.5.3. Regulatory scenario
11.8.5.4. Egypt market estimates and forecasts, 2018 - 2030 (USD Million)
11.8.6. Israel
11.8.6.1. Key country dynamics
11.8.6.2. Competitive scenario
11.8.6.3. Regulatory scenario
11.8.6.4. Israel market estimates and forecasts, 2018 - 2030 (USD Million)
11.8.7. Kuwait
11.8.7.1. Key country dynamics
11.8.7.2. Competitive scenario
11.8.7.3. Regulatory scenario
11.8.7.4. Israel market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 12. Competitive Landscape
12.1. Competition Categorization
12.1.1. Market Leaders
12.1.2. Emerging Players
12.2. Company Market Share/Assessment Analysis, 2024
12.3. Company Profiles
12.3.1. Accell Clinical Research, LLC
12.3.1.1. Company overview
12.3.1.2. Financial performance
12.3.1.3. Service benchmarking
12.3.1.4. Strategic initiatives
12.3.2. Genpact
12.3.2.1. Company overview
12.3.2.2. Financial performance
12.3.2.3. Service benchmarking
12.3.2.4. Strategic initiatives
12.3.3. Criterium, Inc.
12.3.3.1. Company overview
12.3.3.2. Financial performance
12.3.3.3. Service benchmarking
12.3.3.4. Strategic initiatives
12.3.4. ICON plc
12.3.4.1. Company overview
12.3.4.2. Financial performance
12.3.4.3. Service benchmarking
12.3.4.4. Strategic initiatives
12.3.5. iuvo BioScience, LLC.
12.3.5.1. Company overview
12.3.5.2. Financial performance
12.3.5.3. Service benchmarking
12.3.5.4. Strategic initiatives
12.3.6. WuXi AppTec
12.3.6.1. Company overview
12.3.6.2. Financial performance
12.3.6.3. Service benchmarking
12.3.6.4. Strategic initiatives
12.3.7. Medpace
12.3.7.1. Company overview
12.3.7.2. Financial performance
12.3.7.3. Service benchmarking
12.3.7.4. Strategic initiatives
12.3.8. Charles River Laboratories
12.3.8.1. Company overview
12.3.8.2. Financial performance
12.3.8.3. Service benchmarking
12.3.8.4. Strategic initiatives
12.3.9. Laboratory Corporation of America Holdings
12.3.9.1. Company overview
12.3.9.2. Financial performance
12.3.9.3. Service benchmarking
12.3.9.4. Strategic initiatives
12.3.10. Parexel International (MA) Corporation
12.3.10.1. Company overview
12.3.10.2. Financial performance
12.3.10.3. Service benchmarking
12.3.10.4. Strategic initiatives
12.3.11. Freyr
12.3.11.1. Company overview
12.3.11.2. Financial performance
12.3.11.3. Service benchmarking
12.3.11.4. Strategic initiatives
12.3.12. PHARMALEX GMBH
12.3.12.1. Company overview
12.3.12.2. Financial performance
12.3.12.3. Service benchmarking
12.3.12.4. Strategic initiatives
12.3.13. SSI Strategy LLC
12.3.13.1. Company overview
12.3.13.2. Financial performance
12.3.13.3. Service benchmarking
12.3.13.4. Strategic initiatives
12.3.14. Pharmexon
12.3.14.1. Company overview
12.3.14.2. Financial performance
12.3.14.3. Service benchmarking
12.3.14.4. Strategic initiatives
12.3.15. Qvigilance
12.3.15.1. Company overview
12.3.15.2. Financial performance
12.3.15.3. Service benchmarking
12.3.15.4. Strategic initiatives
12.3.16. BlueReg
12.3.16.1. Company overview
12.3.16.2. Financial performance
12.3.16.3. Service benchmarking
12.3.16.4. Strategic initiatives
12.3.17. Cambridge Regulatory Services
12.3.17.1. Company overview
12.3.17.2. Financial performance
12.3.17.3. Service benchmarking
12.3.17.4. Strategic initiatives
12.3.18. VCLS
12.3.18.1. Company overview
12.3.18.2. Financial performance
12.3.18.3. Service benchmarking
12.3.18.4. Strategic initiatives
°ü·ÃÀÚ·á